ImmunityBio, Inc. (IBRX) Tops Q3 EPS by 4c

ImmunityBio, Inc. (NASDAQ: IBRX) reported Q3 EPS of ($0.07), $0.04 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $32.06 million versus the consensus estimate of $31.88 million.

For earnings history and earnings-related data on ImmunityBio, Inc. (IBRX) click here.

You May Also Be Interested In

• Sprinklr (CXM) Tops Q2 EPS by 1c, Offers Guidance
• Popular stocks: MU DELL SPCX INTC PLTR NFLX SOFI AVGO ASTS ORCL MSTR SMCI
• Google launches Gemini 3.8 Flash and a cybersecurity model variant